Abeona Therapeutics (NASDAQ: ABEO) Price Target Lowered Amid Operational Challenges

• Industrial Alliance Securities has reduced its price target for Abeona Therapeutics (NASDAQ: ABEO) from $20.00 to $15.00.
• The adjustment follows a 14% stock price drop after Abeona Therapeutics reported Q2 revenues of $11.40 million, missing analyst expectations.
• Despite operational challenges with its Zevaskyn cell therapy, Abeona Therapeutics achieved 31% net revenue growth for Zevaskyn and holds a cash position of $146.80 million.

Abeona Therapeutics (NASDAQ: ABEO) is a leading biotechnology company that develops innovative cell and gene therapies for serious diseases. Following its recent updates, Industrial Alliance Securities lowers its price target for Abeona Therapeutics to $15.00 from a previous target of $20.00. When the new target was announced, the stock was trading at $5.90 per share.

The price target adjustment comes after Abeona Therapeutics’ second-quarter earnings report, which led to a 14% drop in its stock price. The company announced revenues of $11.40 million, a figure that missed analyst expectations. This miss helps explain the more cautious short-term outlook from the securities firm, even with a target well above the current price.

Abeona Therapeutics is facing operational challenges with the commercial launch of its Zevaskyn cell therapy. Setbacks include patient scheduling cancellations and manufacturing issues. Although five patients were treated in the second quarter, revenue was recognized for only four because one treatment batch had a cell yield below the billing threshold.

Despite these difficulties, Zevaskyn's net revenue grew by 31% to $11.40 million compared to the first quarter. Since its launch, 12 patients have been treated, and Abeona Therapeutics has activated seven Qualified Treatment Centers across the country. This expansion meets the company's stated goal for the year.

Abeona Therapeutics reports a cash position of $146.80 million as of June 30, 2026. As highlighted by Seeking Alpha, potential near-term growth could come from its partnerships with Ultragenyx (NASDAQ: RARE) and Taysha (NASDAQ: TSHA). These collaborations could result in milestone and royalty payments if specific approval and sales goals are achieved.